[
    [
        {
            "time": "2023-10-18",
            "original_text": "天坛生物注射用重组人凝血因子Ⅶa正式开展一期临床试验",
            "features": {
                "keywords": [
                    "天坛生物",
                    "注射用重组人凝血因子Ⅶa",
                    "一期临床试验"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "天坛生物注射用重组人凝血因子Ⅶa正式开展一期临床试验",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "天坛生物：“注射用重组人凝血因子VIIa”已通过伦理审查、完成临床入组前准备等工作",
            "features": {
                "keywords": [
                    "天坛生物",
                    "注射用重组人凝血因子VIIa",
                    "伦理审查",
                    "临床入组前准备"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "天坛生物：“注射用重组人凝血因子VIIa”已通过伦理审查、完成临床入组前准备等工作",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "天坛生物(600161.SH)：“注射用重组人凝血因子VIIa”已通过伦理审查、完成临床入组前准备等工作",
            "features": {
                "keywords": [
                    "天坛生物",
                    "600161.SH",
                    "注射用重组人凝血因子VIIa",
                    "伦理审查",
                    "临床入组前准备"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "天坛生物(600161.SH)：“注射用重组人凝血因子VIIa”已通过伦理审查、完成临床入组前准备等工作",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]